The overall expression trends observed in our study were strongly concordant with UALCAN-derived results: MAP3K1, MAP2K4, and TP53 were likewise reduced in tumor tissues—particularly in HER2-enriched and basal-like/TNBC subtypes—while PPM1D, LMTK3, and TGFB1 showed increased expression relative to normal controls. The gene discussed is MAP2K4; the disease is neoplasm.